Management of Diabetes Mellitus and Hypertension

Blood Pressure Management

• The American Heart Association recommends that patients with both diabetes mellitus and hypertension should be treated with a regimen that includes either an ACE inhibitor or an ARB as first-line therapy, with a blood pressure target of <130/80 mmHg 1, 2, 3
• Blood pressure should be measured at every routine diabetes visit, with elevated readings (≥130/80 mmHg) confirmed on a separate day, as recommended by the American Diabetes Association 1, 4
• The European Society of Cardiology recommends a target blood pressure for patients with diabetes of <130/80 mmHg 1, 3, 5
• In elderly patients (>65 years), a more moderate systolic target of 130-139 mmHg is recommended to avoid complications, according to the European Heart Journal 3, 5
• For BP 130-139/80-89 mmHg, lifestyle modifications alone should be started for a maximum of 3 months, as suggested by the American Heart Association 1, 2
• If targets are not achieved after 3 months, pharmacological therapy should be initiated, as recommended by the American Heart Association 2, 3
• For BP ≥140/90 mmHg, immediate initiation of both lifestyle modifications and pharmacological therapy is recommended, according to the European Heart Journal 1, 2, 5
• The first-line pharmacological approach should include an ACE inhibitor or an ARB, with a thiazide/thiazide-like diuretic added as one of the first two drugs, as recommended by the American Heart Association 1, 2, 5, 6
• Calcium channel blockers and/or β-blockers should be added as needed to achieve target blood pressure, according to the American Heart Association 1, 3
• Renal function and serum potassium should be monitored within the first 3 months of starting ACE inhibitors, ARBs, or diuretics, then every 6 months if stable, as recommended by the American Heart Association 2, 3

Lifestyle Modifications

• Weight control is recommended if overweight/obese, as suggested by the American Heart Association and the American Diabetes Association 1, 2, 4
• A DASH-style dietary pattern with reduced sodium intake (1200-2300 mg/day) is recommended, according to the American Heart Association 2, 7
• Increased consumption of fresh fruits, vegetables, and low-fat dairy products is recommended, as suggested by the American Heart Association 1, 3
• At least 150 minutes of moderate-intensity aerobic activity or 90 minutes of vigorous exercise weekly, distributed over at least 3 days, is recommended, according to the American Heart Association 8, 7
• Moderate alcohol intake (limit to one drink for women, two for men daily) is recommended, as suggested by the American Heart Association 8

Lipid Management

• A fasting lipid profile should be obtained at diagnosis and annually thereafter, as recommended by the American Diabetes Association and the American College of Cardiology 4, 6
• For patients with diabetes at very high CV risk, an LDL-C target <1.4 mmol/L (<55 mg/dL) with at least 50% reduction from baseline is recommended, according to the European Society of Cardiology 5
• For patients with diabetes over age 40 with CV risk factors, an LDL-C target <100 mg/dL (2.6 mmol/L) is recommended, as suggested by the American Diabetes Association and the American College of Cardiology 4, 7
• Statin therapy is recommended regardless of baseline lipid levels for diabetic patients with overt CVD or those over 40 years with one or more CV risk factors, according to the American Diabetes Association and the American College of Cardiology 4, 6
• Ezetimibe should be considered if target LDL-C is not achieved with maximal tolerated statin dose, as recommended by the European Society of Cardiology and the American College of Cardiology 5, 9

Newer Antidiabetic Medications with CV Benefits

• SGLT2 inhibitors are recommended for patients with T2DM and CVD or at high CV risk, according to the European Society of Cardiology 5
• GLP-1 receptor agonists are recommended for patients with T2DM and CVD or at high CV risk, as suggested by the European Society of Cardiology 5
• Empagliflozin is specifically recommended to reduce the risk of death in patients with T2DM and CVD, according to the European Society of Cardiology 5

Monitoring and Follow-up

• Blood pressure should be monitored at every routine diabetes visit, as recommended by the American Diabetes Association and the American Heart Association 1, 4
• Orthostatic blood pressure measurements should be checked when clinically indicated, according to the American Heart Association 1, 3
• Renal function and serum potassium should be monitored within 3 months of starting ACE inhibitors, ARBs, or diuretics, then every 6 months if stable, as recommended by the American Heart Association 2, 3
• Cardiovascular risk factors should be assessed systematically at least annually, according to the American College of Cardiology and the American Heart Association 6, 9

Special Considerations

• In patients with diabetic nephropathy, ACE inhibitors or ARBs have shown benefits in slowing disease progression, as suggested by the American Heart Association 2
• Multiple-drug therapy is generally required to achieve blood pressure targets in most patients, according to the American Heart Association 1, 2
• ACE inhibitors and ARBs are contraindicated during pregnancy due to the risk of fetal damage, as recommended by the American College of Cardiology and the American Heart Association 6, 9

Management of Hypertension in Diabetic Patients

Rationale for Adding a Diuretic

• The American Diabetes Association and other guidelines recommend that most patients with diabetes and hypertension require two or more drugs at maximal doses to achieve blood pressure targets, with a blood pressure target of <140/90 mmHg (or <130/80 mmHg if tolerable) 10, 11
• The addition of a fourth medication is necessary when three agents at maximal doses are insufficient to achieve blood pressure control, with the American Heart Association suggesting a thiazide or thiazide-like diuretic as one of the first two drugs in diabetic hypertensive patients 10, 11

Why Thiazide Diuretics Are the Appropriate Choice

• Thiazide diuretics have strong outcome trial evidence showing reduction in cardiovascular events and mortality in diabetic patients with hypertension, particularly in combination with ACE inhibitors and calcium channel blockers 12, 13, 14
• Diuretics are effective in elderly patients and address the volume component of hypertension that is almost always present in diabetic patients, with low-dose thiazide therapy minimizing metabolic side effects while maintaining antihypertensive efficacy 13, 14

Specific Diuretic Recommendations and Monitoring Requirements

• Low-dose thiazide therapy, such as chlorthalidone 12.5-25mg daily or hydrochlorothiazide 12.5-25mg daily, is recommended to minimize metabolic side effects while maintaining antihypertensive efficacy 13
• Monitoring of serum electrolytes, particularly potassium, and renal function is necessary approximately 1-2 weeks after initiating diuretic therapy, with each dose increase, and at least yearly thereafter, due to the increased risk of electrolyte abnormalities with concurrent ACE inhibitor use 10, 11

Common Pitfalls to Avoid

• High-dose thiazides should be avoided, as metabolic side effects increase substantially without proportional blood pressure benefit, with the American Diabetes Association recommending low-dose thiazide therapy 13
• The combination of ACE inhibitor plus ARB should be avoided, as this combination increases adverse events without additional cardiovascular benefit, according to the American Heart Association 10

Bedtime Dosing Strategy

• Administering one or more antihypertensive medications at bedtime, such as the calcium channel blocker or ACE inhibitor, can improve blood pressure control, as recommended by the American Diabetes Association 10